Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
噬菌体作为慢性假单胞菌气道疾病的预测生物标志物
基本信息
- 批准号:10723956
- 负责人:
- 金额:$ 19.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-22 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdultAdvisory CommitteesAirway DiseaseAntibiotic ResistanceAntibiotic TherapyAntibioticsAntimicrobial ResistanceAntimicrobial susceptibilityAztreonamBacterial ChromosomesBacteriophagesBiological MarkersBiological TestingBiologyBiometryBronchiectasisCaringChronicClinicalClinical ResearchClinical TrialsClinical Trials DesignCystic FibrosisCystic Fibrosis sputumDataDenmarkDevelopmentDevelopment PlansDiseaseDisease ManagementEnvironmentEvolutionFoundationsFutureGenomicsGrowthHumanImpairmentIn VitroInfectionInhalationInovirusLongitudinal cohortLungLung diseasesLung infectionsMeasuresMediatingMentorsMicrobial BiofilmsMicrobiologyMinimum Inhibitory Concentration measurementNonlyticOrganismPatient CarePatientsPhenotypePhylogenyPhysiciansPolysaccharidesPopulationProphagesPseudomonasPseudomonas aeruginosaPseudomonas aeruginosa infectionPublishingPulmonary Cystic FibrosisPulmonologyRecurrenceResearchResistanceRespiratory DiseaseRespiratory FailureRespiratory Tract InfectionsRetrospective cohortSamplingScientistSerial PassageSputumTestingTherapeuticTimeTobramycinTracheostomy procedureTrainingTranslational ResearchVirionVirus Integrationantibiotic tolerancebiobankcareercareer developmentchronic infectionclinical carecohortcystic fibrosis airwaycystic fibrosis infectioncystic fibrosis patientsemerging antibiotic resistanceexperienceexperimental studygene functiongenome sequencingimproved outcomein vivoinsightmucoidnovelnovel therapeuticspathogenpersonalized approachpredicting responsepredictive markerprospectivepulmonary functionresistance generespiratoryresponseresponse biomarkerskillstranslational medicinetreatment strategywhole genome
项目摘要
PROJECT SUMMARY / ABSTRACT
Despite major advances in therapy, pulmonary disease continues to dominate the clinical course
of patients with cystic fibrosis (CF). All patients with CF develop chronic lung infections, with
Pseudomonas aeruginosa (Pa) becoming a predominant organism in adulthood. Even in the face of
chronic inhalational antibiotic therapy to target Pa in the lungs, CF patients experience intermittent
pulmonary exacerbations with stepwise decline in lung function leading to eventual respiratory failure.
Novel treatment strategies are urgently needed to address the damaging effects of chronic Pa in the
lungs of CF patients. This will allow for all patients with CF to fully benefit of an evolving therapeutic
landscape to address their defective CF gene function.
I discovered the presence of the Pa filamentous (Pf) bacteriophage, in cohorts of patients with CF
in Stanford and Denmark. Pf was associated with chronicity of Pa and more severe exacerbations
(Burgener et al, Science Translational Medicine 2019). This constituted the first demonstration of the
involvement of bacteriophage in human lung disease. This proposal aims to delve into the mechanisms
behind these associations. Given the known shortcomings of chronic inhalational antibiotic therapy, I
will test the hypothesis that in the lung Pf provides antibiotic tolerance and is a predictive biomarker to
guide in choosing effective inhalational therapeutics. The first aim utilizes banked respiratory Pa
isolates to (1a), assess antibiotic tolerance under conditions present in the lung, (1b) perform whole
genome sequencing to assess for presence of antibiotic resistance genes and (1c) perform evolutionary
experiments to investigate acquisition of resistance as a function of Pf. The second aim will assess Pf
as a lung disease predictive biomarker in (2a) a retrospective cohort evaluating response to
exacerbations therapy and (2b) perform a cross-over clinical trial to assess for differential effects of Pf
on lung function. This proposal, supported by exciting and novel preliminary data, promises to provide
rationale and mechanistic foundation for Pf to be used as a predictive biomarker to guide inhalational
antibiotic choices in CF airway disease management.
The proposed research draws upon my prior experience in clinical pulmonary medicine and
growing expertise in translational research. Along with my mentors and advisory committee, I present
a comprehensive career development plan for didactics and technical training in microbiology,
genomics, and clinical trial design and biostatistics. This training, along with the clinical studies and
experiments outlined, will allow me to develop skills crucial for my transition to an independent
translational research career focused on bringing new therapies and treatment strategies for
transformative management of CF lung disease.
项目总结/摘要
尽管在治疗方面取得了重大进展,但肺部疾病仍在临床病程中占主导地位
囊性纤维化(CF)患者。所有CF患者均发生慢性肺部感染,
铜绿假单胞菌(Pa)在成年期成为优势微生物。即使面对
慢性吸入性抗生素治疗以靶向肺部Pa,CF患者经历间歇性
肺部恶化伴肺功能逐步下降,最终导致呼吸衰竭。
迫切需要新的治疗策略来解决慢性Pa在肺动脉中的损害作用。
CF患者的肺部。这将使所有CF患者能够充分受益于不断发展的治疗方法
景观,以解决他们的缺陷CF基因功能。
我在CF患者队列中发现了Pa丝状噬菌体的存在
在斯坦福大学和丹麦。Pf与Pa的慢性化和更严重的急性加重相关
(Burgener et al,Science Translational Medicine 2019)。这是第一次展示
噬菌体与人类肺部疾病关系这项建议的目的是深入探讨机制,
这些协会的背后。鉴于慢性吸入抗生素治疗的已知缺点,我
将检验肺中Pf提供抗生素耐受性并且是预测性生物标志物的假设,
指导选择有效的吸入疗法。第一个目的是利用库存的呼吸Pa
分离株,以(1a),评估肺中存在的条件下的抗生素耐受性,(1b)进行整体
基因组测序以评估抗生素抗性基因的存在,以及(1c)进行进化分析,
第二个目标是评估Pf
作为肺部疾病预测生物标志物,在(2a)回顾性队列中评估对
急性加重治疗和(2b)进行交叉临床试验,以评估Pf的差异效应
对肺功能的影响这一提议得到了令人兴奋和新颖的初步数据的支持,有望提供
将Pf用作指导吸入给药的预测性生物标志物的原理和机制基础
CF气道疾病管理中的抗生素选择。
本研究基于我之前在临床肺医学方面的经验,
在翻译研究中不断增长的专业知识。沿着我的导师和顾问委员会,
微生物学教学和技术培训的全面职业发展计划,
基因组学、临床试验设计和生物统计学。这项培训,沿着临床研究,
概述的实验,将使我能够发展对我过渡到一个独立的关键技能,
翻译研究职业生涯的重点是带来新的疗法和治疗策略,
CF肺病的变革管理。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Bendig Burgener其他文献
Elizabeth Bendig Burgener的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.9万 - 项目类别:
Research Grant